Abstracts

Increased levels of FGF21 and GDF15 Are Associated With Severity of NAFLD in People With HIV

Background: Non-alcoholic fatty liver disease (NAFLD) poses a significant health burden in people with HIV (PWH). Fibroblast growth factor 21 (FGF21) is an important regulator of hepatic lipid and glucose metabolism. Higher levels have been associated with hepatic steatosis and liver fibrosis in the general population. Growth differentiation factor 15 (GDF15) is upregulated in chronic…

Race/Ethnicity and Risk of NAFLD and Clinically Significant Fibrosis in Persons Living With HIV

Background: Racial and ethnic differences in non-alcoholic fatty liver disease (NAFLD) prevalence are well described in the general population, with Hispanics having the highest and African Americans having the lowest NAFLD prevalence. Whether similar disparities exist in persons with HIV (PWH) with NAFLD is largely unknown. We investigated racial and ethnic differences in the prevalence…

Chronic Hepatitis B Increases Mortality Risk in COVID-19 While Vaccination Is Protective

Background: Chronic hepatitis B virus (HBV) infection is considered a risk factor for severe SARS-CoV-2 infection (COVID-19); however, there is conflicting evidence regarding its impact on COVID-19 outcomes in dually infected individuals. Furthermore, while COVID-19 vaccination has been associated with a lower risk of death and adverse outcomes in the general population, its effect on…

Loss of Serologic Response in Young People With HIV (PWH) Who Had Undergone HBV Revaccination

Background: We previously have shown in a clinical trial that PWH who had achieved virologic and immunologic responses with ART and were randomized to receive three double-dose (40-µg) HBV vaccine (Engerix) achieved a significantly higher seroresponse rate (anti-HBs antibody titer ≥10 mIU/ml) and high-titer (≥100 mIU/ml) seroresponse rate than PWH who received three standard-dose (20-µg)…

Risk of Liver-Related Events in Individuals With HBV/HIV Coinfection With and Without HDV

Background: Up to 10% of individuals with human immunodeficiency virus (HIV) are coinfected with hepatitis B virus (HBV). Limited data are available describing the natural history of triple infection with HBV/HIV/hepatitis delta virus (HDV). This study examines baseline liver health, HDV prevalence, and the risk of liver-related events in individuals in United States (US) administrative…

Simultaneous Start Strategy With BIC/FTC/TAF in Individuals With HIV/HCV Coinfection in China

Background: Highly Active Antiretroviral treatment (ART) with Direct-acting antiviral agents (DAAs) has demonstrated high efficacy and favorable safety profile in HIV/HCV co-infected individuals with HIV viral suppression and stable immune status. However there is great need in rapid initiation of ART and anti-HCV treatment regardless of HIV viral suppression status and CD4 T cell count…